I
mmunological memory is one of the hallmarks of the adaptive immune response and a vital tool in the fight against infection, allowing rapid and efficient clearance of a previously encountered antigen following secondary exposure (Fig. 1 ). In the setting of transplantation, it has long been known that the presence of preformed alloreactive antibodies may result in hyperacute allograft rejection (1, 2) . The potential of alloantigen-reactive memory T cells (Tm) to elicit allograft rejection was first identified in experimental models in the 1970s (3) (4) (5) . Despite these observations, Tm have only recently been identified as a potentially important subset in the human immune response to an allograft due to their presence prior to transplantation.
IDENTIFICATION OF ALLOREACTIVE MEMORY T CELLS PRIOR TO TRANSPLANTATION
The presence of Tm capable of responding to alloantigen in healthy individuals was shown as far back as 1990 when Lombardi and colleagues split the peripheral blood T-cell population into LFA-3 ϩ memory and LFA-3 Ϫ naïve populations (6) . In response to MHC-incompatible stimulator cells in a mixed lymphocyte reaction (MLR), it was shown that both memory and naïve populations proliferated in response to alloantigen. Interestingly, it was noted that the LFA-3 ϩ "memory" population responded primarily within the first 3 days after stimulation, therefore exhibiting the accelerated kinetics characteristic of secondary responses. More recently, alloreactive Tm have been shown to participate in the rejection process in heart, kidney, and liver transplant recipients where the presence of pretransplant Tm has been linked to both an increase in the incidence and severity of rejection episodes (7) (8) (9) (10) . Indeed, two reports have shown a correlation between the pretransplant frequency of alloreactive Tm as measured in vitro by interferon-␥ (IFN-␥) production and the posttransplant risk of acute renal allograft rejection (11, 12) . Furthermore, Augustine and coworkers reported a correlation between pretransplant Tm and the risk of reduced allograft function 12 months following receipt of a kidney transplant (12) .
These studies suggest that Tm may be capable of mediating early acute rejection episodes. Furthermore, the contribution of Tm to late graft loss suggests that although the high induction levels of immunosuppressive drugs may be able to suppress acute rejection, Tm persist and may be capable of causing long-term damage resulting in chronic rejection of an allograft when maintenance immunosuppression is tapered. Alternatively or additionally, the activation of T cells that takes place during early rejection episodes despite immunosuppression (13) may lead to the formation of memory populations that persist and contribute to late or chronic graft loss.
HOW ARE ALLOREACTIVE Tm GENERATED IN NON-SENSITIZED INDIVIDUALS?
In order to generate immunological memory, it was thought that it was necessary for the immune system to have previously encountered the antigen against which the mem-ory response was raised. In the transplantation setting, memory to alloantigen can be induced by pregnancy, a foreign blood transfusion, or a previous transplant. However, the presence of alloreactive Tm prior to transplantation in nonsensitized patients raises the question of how Tm were generated in this situation. Recently, accumulating evidence has led to the proposal that there are two potential mechanisms by which alloreactive T-cell memory may be generated without specific exposure to alloantigen, namely crossreactivity with infectious agents that may occur through the processes of molecular mimicry (14) or bystander proliferation (15) and homeostatic proliferation (16) .
Adams et al. have provided strong evidence in support of alloreactive Tm generation by crossreactivity triggered by an infection. In an elegant series of experiments, it was shown that CD8 ϩ H2 d alloreactive Tm were generated in H2 b mice following multiple viral infections (17) . Crossreactivity between viral and alloantigens has also been shown in splenocyte populations derived 8 days after lymphocytic choriomeningitis virus (LCMV) infection in mice (18) . Furthermore, CD4
ϩ T cell crossreactivity has been demonstrated between Leishmania major antigens and H2 p alloantigen (19) . Such crossreactivity appears not to be restricted to rodents as in humans; cytomegalovirus (CMV) and EpsteinBarr virus (EBV) seropositive patients have been shown to possess alloreactive cytotoxic T cells (20, 21) . Further analysis has shown that HLA-B8 restricted CD8 ϩ T cells specific for an EBV epitope showed in vitro crossreactivity with alloantigens including HLA-B44 (20) . It is therefore not surprising that HLA-B8, B44 transplant donor-recipient pairings have been identified as an "immunological pairing" with a predicted worse prognosis for allograft survival than transplants between patients possessing other MHC haplotypes (22) . Thus, crossreactivity between alloantigen and infectious agents suggests that Tm capable of responding to alloantigen may be generated by prior infection.
In addition to prior exposure to pathogens, Tm may also be generated by the process of homeostatic proliferation. It has been well documented that T cells undergo homeostatic proliferation when transferred into lymphopenic recipient mice (23) and that under such conditions naïve T cells can form a population of cells with a memory phenotype (16, 24 -28) . Indeed, such T cells possess properties consistent with antigen experienced cells such as the ability to infiltrate allografts in mice lacking secondary lymphoid organs (naïve cells are incapable of doing so) (25) . In the clinical setting, should an individual suffer a lymphopenic episode such as that which may occur following thymic release of the first wave of naïve T cells in neonates into an empty lymphoid compartment (29) , during infection (30) , following treatments such as chemotherapy, in older recipients where thymic involution has taken place (31, 32) , or importantly in transplantation where aggressive T-cell depletion strategies such as antithymocyte globulin or anti-CD52 antibodies are used (33, 34) , homeostatic mechanisms replenishing the Tcell pool may render these individuals particularly vulnerable to Tm-mediated rejection.
Clearly, immunological crossreactivity and homeostatic proliferation may both result in the generation of alloreactive Tm. However, comparisons of Tm generated in such a manner compared to Tm resulting from exposure to alloantigen are scarce. One may expect that responses by alloreactive Tm that have not experienced alloantigen to be suboptimal as compared to alloantigen experienced Tm as highaffinity alloreactive clones would not be preferentially selected for the Tm pool following their generation by pathogenic stimuli or via homeostatic proliferation. In addition, the precursor frequency of Tm generated in the absence of alloantigen is likely to be lower than Tm generated by specific alloantigen exposure. In accordance with these predictions, Chalasani et al. demonstrated that homeostatically generated Tm suboptimally rejected cardiac grafts compared with al- loantigen experienced Tm (25) . Furthermore, data provided by both Adams et al. and Pantenburg et al. suggest that fewer alloreactive Tm are generated following crossreactivity than seen following exposure to alloantigen as measured by enzyme-linked immunosorbent assays for interferon (IFN)-␥ production (17, 19) . Nevertheless, Pantenburg et al. demonstrated in vivo rejection of skin allografts by cross-reactive Tm in Leishmania major immune mice was no different to second-set rejection by mice that had previously rejected a donor-type skin allograft (19) .
MEMORY T-CELL MAINTENANCE AND SUBSETS
Once generated, Tm persist until further encounter with the same or cross-reactive antigen. The maintenance of a single cell over a long period of time, potentially the lifetime of a host, would seem improbable. In fact, memory cells undergo a basal level of homeostatic proliferation likely requiring low-affinity self-MHC interactions as a stimulus (35, 36) . In addition, Tm rely on anti-apoptotic molecules such as bcl-x L and bcl-2 (37, 38) , together with the cytokines interleukin (IL)-7 and IL-15 for their maintenance and survival (26, 39 -42) .
Two distinct subsets of Tm have been identified in the maintenance phase of a memory response, so-called central and effector memory cells, T CM and T EM , respectively (43) (44) (45) . T EM are found in non-lymphoid tissue, are CD62L and CCR7 low, and exhibit immediate ex-vivo cytotoxicity. In contrast, T CM express high levels of both CD62L and CCR7 and are therefore found predominantly in lymphoid tissue. Unlike T EM , T CM require restimulation in order to rapidly acquire effector function (43, 44, 46) .
The relationship between T EM and T CM is unclear. One possibility is that T CM are generated as a result of further T EM differentiation (47) . Equally, it is has been reported that these two subsets, T CM and T EM , are distinct populations that have differentiated along separate pathways following antigen recognition (48, 49) .
However, once T CM and T EM are formed, it is likely that they have distinct but complementary roles in the secondary response to antigen. For example, T EM may provide an immediate but limited response to antigen in non-lymphoid tissues with T CM providing a follow-up boost to the response after reactivation in the secondary lymphoid tissue (47, 50) . Alternatively, T EM may be just as able to mediate a potent recall response to antigen as T CM. Both T CM and T EM have been shown to be capable of killing in vivo following restimulation (51) with T CM being the more efficient killers. However, others have reported that T EM are also capable of mounting significant recall responses (52, 53) .
MEMORY T CELLS INHIBIT THE INDUCTION OF TOLERANCE TO ALLOGRAFTS
The quest to induce tolerance to foreign organ transplants has led to the generation of a number of successful protocols in rodent models (54 -62) . However, when these protocols have been taken into large animal and non-human primate models, tolerance has been notoriously difficult to achieve (63, 64) . One possible explanation for this is that large animal models may possess significant populations of Tm that negatively impact the induction of tolerance.
Indeed, this has been shown to be the case in rodents as Tm generated in mice sensitized with a donor-type skin graft were capable of mediating the rejection of donor-type cardiac allografts in the presence of anti-CD154 mAb, a therapy that had proved effective at permitting tolerance induction in non-sensitized recipients (65, 66) . Importantly, Adams et al. have shown that CD8 ϩ T-cell memory generated by cross reactivity rather than priming with donor alloantigen may also cause rejection of skin grafts despite the use of a known tolerance inducing protocol (17) . In these studies, the authors demonstrated that sequential infection with sublethal doses of the pathogenic viruses LCMV, vaccinia virus (VV), and vesicular stomatitis virus (VSV) resulted in the generation of alloreactive Tm. Furthermore, using a protocol involving treatment of recipient animals with CTLA4-Ig, anti-CD40L mAb, busulfan, and donor bone marrow infusion, which has been shown to induce donor-specific tolerance in naïve animals, it was demonstrated that the presence of CD8
ϩ Tm generated by viral crossreactivity abrogated the induction of tolerance in most mice. These experiments suggest that Tm generated by crossreactivity may form a barrier to the induction of tolerance using agents successful in naïve animals.
The ability of Tm to disrupt tolerance induction is not confined to those generated following exposure to alloantigen or pathogens; Tm formed as a result of homeostatic proliferation have also been shown to be counter productive for tolerance induction. Wu and colleagues showed using a number of tolerance induction protocols incorporating blockade of either CD28/B7, CD40/CD40L interactions or a combination of both agents that homeostatically generated Tm were able to elicit cardiac allograft rejection due to a reduced reliance on CD28 costimulation (16) .
Taken together, these data provide strong support for the presence of alloreactive Tm prior to transplantation having a negative impact on subsequent tolerance induction strategies through whichever pathways such Tm are generated. Considering the likelihood of a transplant recipient having been exposed to viruses such as EBV, cytomegalovirus, herpes simplex virus, and influenza, it is perhaps predictable that therapies based on the subtle manipulation of alloreactive naïve T-cell responses alone will not be sufficient to invoke long-term allograft tolerance in clinical transplantation. It is therefore necessary to investigate how memory and naive T-cell responses differ to reveal potential strategies that could be employed to target alloreactive Tm responses.
THE RECALL RESPONSE AND ITS POTENTIAL IN ALLOGRAFT REJECTION
The response of Tm to recall antigen has many unique properties that confer a distinct advantage over the naïve response (Fig. 2) . For example, Tm have a lower activation threshold than naïve cells, resulting in the ability to respond to low affinity/avidity interactions and therefore far lower doses of antigen (35, 67, 68 ). In addition, Tm can become activated sufficiently to induce graft rejection in the absence of secondary lymphoid tissues (25) and show differential adhesion molecule (69), lymphokine (70) , chemokine (43, 71, 72) , and chemokine receptor expression compared to naive T cells that may alter their homing potential and allow rapid migration to sites of inflammation such as an organ transplant. CD8 ϩ Tm have been shown to be able to rapidly develop direct cytotoxicity and preferentially kill target cells via the granular exocytosis pathway as opposed to via FAS/FASL or TNF-␣ pathways (51, 70, (73) (74) (75) (76) . Furthermore, Tm may be poised to initiate a rapid DTH response to alloantigen as they have been reported to have high prestored levels of both inflammatory cytokines and chemokines, such as IFN-␥ and RANTES, that are released very quickly upon reactivation (10, 70, 76 -79) .
In addition, both CD4 ϩ and CD8 ϩ Tm can have a Th2 bias following restimulation with antigen. Therefore, in the transplantation setting, the ability of Tm to respond to an allograft by production of Th2 cytokines may contribute to antibody or eosinophil mediated effector mechanisms, thereby altering the course or type of allograft rejection and perhaps the ability to induce tolerance (80 -83) .
STRATEGIES TO INHIBIT MEMORY T-CELL RESPONSES TO AN ALLOGRAFT
In the clinical setting, current therapies induce global immunosuppression that is effective at permitting prolonged survival of foreign organ transplants. Although this broad immunosuppressive strategy has proven remarkably successful at inhibiting acute rejection, it remains unclear to what extent Tm responses are suppressed. The previously mentioned work of Heeger et al. and Augustine et al. demonstrated a correlation between the presence of pretransplant alloreactive Tm and acute rejection episodes that occurred despite immunosuppression, in the latter case tacrolimusand sirolimus-based therapy (11, 12) . Furthermore, leukocyte depletion, such as antithymocyte globulin (ATG), alemtuzumab, or anti-human CD52 mAb treatments, have also been shown to be less able to diminish the memory T-cell pool. Indeed, following leukocyte-depletion treatments, effector memory CD4 ϩ T cells have proved to be the dominant T-cell subset remaining and appear able to initiate rejection episodes in their own right ( [34] ; Tronzkowski and Wood, unpublished observations). However, when the sensitivity of such cells to a variety of immunosuppressive agents was investigated, it was demonstrated that although effector memory CD4
ϩ Tm responses were resistant to steroids, deoxyspergualin and sirolimus, the calcineurin inhibitor tacrolimus, and to a lesser degree cyclosporin A (CsA), were able to inhibit proliferation and cytokine production upon in vitro stimulation (34) . In contrast to this report, it has been shown that deoxyspergualin combined with costimulation blockade may inhibit Tm responses and promote tolerance (17) and that cyclosporine promotes the commitment of T cells to a memory state following naïve T-cell priming (84, 85) . Furthermore, when present at low levels during priming, CsA may result in an enhanced recall response in the subsequent absence of immunosuppression (84, 85) . Therefore, although some conventional immunosuppressive agents may impact the ability of Tm to respond to an allograft, this may depend on the timing and dose of the administered agent.
An alternative to pan-immunosuppression of Tm responses is to develop protocols aimed at inducing antigenspecific tolerance in Tm in much the same way as that reported for naïve T-cell responses. Although Tm may be more refractory to tolerance induction than naive T cells, tolerance can certainly be achieved. For example, Kreuwel et al. demonstrated the induction of tolerance to the influenza derived hemagglutinin (HA) molecule in the presence of HA-specific CD8 ϩ Tm either through treatment with soluble peptide or through cross-presentation of antigen by DCs leading to abortive activation and apoptosis (86) . In addition, peripheral memory CD4 ϩ T cells have been shown to be rendered tolerant through low avidity engagement of the T-cell receptor (87) .
Perhaps more pertinent to the induction of tolerance to foreign organ grafts is the targeting of certain costimulatory molecules during allorecognition. This strategy has been successfully employed in numerous rodent models of transplantation tolerance (88, 89) and has focused primarily on blockade of the CD80/86/CD28 or the CD40/CD154 pathways (56, 57, 61 
Tm show a reduced reliance on CD28/B7 and CD154/CD40 costimulation. However, many novel costimulation pathways have now been characterized, some of which are displayed in the table above. Elucidation of those pathways important for Tm activation may provide novel targets for tolerance induction protocols based on costimulation blockade.
Expression of costimulatory molecules and their ligands on immune cells only. T, T cell; Treg, regulatory T cell; Tm, memory T cell; TCM, central memory T cell; B, B cell; NK, natural killer cell; DC, dendritic cell; iDC, immature dendritic cell; M, macrophage; Mo, monocyte; E, eosinophil. costimulation (90) . Indeed, Tm have been demonstrated to be less dependent on the B7/CD28 pathway and independent of the CD40/CD154 costimulation pathway (91) . Nonetheless, despite Tm having less of a requirement for CD80/86 and CD40 engagement, Tm may be dependent on other costimulatory pathways for the complete acquisition of effector function which may be potential targets for blockade (Table 1) . For example the ICOS/ICOSL pathway has been implicated in both CD4
ϩ and CD8 ϩ memory responses (92, 93) . Also, 4 -1BB/4 -1BBL interactions have been shown to be important in CD8
ϩ T-cell recall responses (94, 95) and it has been suggested that there may be a significant contribution of OX40/OX40L interactions in memory CD4 ϩ T-cell responses (95, 96) . Encouragingly, it has been shown that prolonged cardiac allograft survival could be achieved following combined CD28-B7 and OX40-OX40L blockade in the presence of adoptively transferred effector T cells (96) . Furthermore, blockade of CD27-CD70 costimulatory interactions was reported to lead to indefinite allograft survival despite the presence of memory CD8 ϩ T cells (97) . Therefore, it appears probable that Tm do rely on costimulatory molecules to function optimally but that that such interactions may be distinct from those utilized during a naive T-cell response (Fig. 3) . Further elucidation of the costimulatory molecule requirements for Tm may lead to further pathways that can be targeted to manipulate Tm responses to allografts in addition to those already successful at preventing transplant rejection mediated by naive T cells.
Finally, many tolerance inducing protocols rely on the generation and/or expansion of donor-reactive regulatory T cells to both induce and maintain long-term tolerance to allografts (98) . However, one constraint is that the potential alloreactive effector T-cell pool must be reduced to "tip" the balance in favor of tolerance rather than rejection (99) . Although the influence of regulatory T cells on Tm during a response to alloantigen is relatively unknown, Dai et al. observed that antigen-induced CD25 ϩ CD4 ϩ regulatory T cells were able to specifically suppress Tm responses to allogeneic skin grafts through CD30 mediated apoptosis (100). It has also been shown that following transplantation of allogeneic islets into the testis under the cover of CD40/CD40L costimulation blockade, tolerance to both the islets and subsequent skin allografts was achieved with a significant reduction but importantly not an abolition of memory T-cell generation (101, 102) . Tolerance was mediated by CD25 ϩ
CD4
ϩ T cells, which could be broken through either the depletion of CD25 ϩ T cells or through the adoptive transfer of exogenous memory CD8
ϩ T cells (102) suggesting that, as with naive T cells, the balance between the numbers of Tm and regulatory T cells is critical in determining tolerance versus rejection.
In summary, despite the distinct properties of alloreactive Tm conferring perhaps a more severe challenge for the induction of tolerance, there is accumulating evidence that suggests that, under the right conditions, tolerance to a foreign organ transplant in the presence of Tm may be achieved.
CONCLUSION
To develop protocols that are capable of inducing tolerance to alloantigen in the presence of alloreactive T-cell memory, the recall response of such cells requires extensive investigation. The elucidation of factors such as the location and environment of alloantigen recognition by different subsets of CD4 ϩ and CD8 ϩ Tm; the role of costimulatory molecules; the trafficking of Tm prior to, during, and after allograft transplantation; and other issues such as the ability of CD4 ϩ
CD25
ϩ cells to regulate Tm responses are needed. It is clear that we are still far from being able to fully appreciate the role of Tm in allograft rejection and resistance to tolerance induction. However, there is cause for optimism that the further characterization of Tm responses to allografts may provide potential targets for immune therapies aimed at inducing tolerance to a foreign organ transplant in the presence of memory T cells. Tm may utilize novel costimulatory pathways to achieve an activated state enabling them to elicit rapid graft rejection. Current evidence has identified CD27/ CD70, ICOS/ICOSL, OX40/OX40L, and 4 -1BB/4 -1BBL interactions as being potentially important in the Tm response. Such costimulation pathways may be constitutively available to naïve T cells or only become available following activation (Induced costimulation pathways). Costimulation molecules may subsequently be downregulated on Tm populations. Alternatively, Tm may maintain expression of molecules such as ICOS so that costimulation pathways such as ICOS/ICOSL interactions are constitutively available and may permit Tm activation.
